by Usha Govindarajulu | Nov 9, 2022 | Biostatistics, Blog, COVID-19, Healtcare, Usha Govindarajulu
November 9, 2022 In a recent article from November 1 in Science Immunology, the authors reported on their analysis of T-cell immunity four weeks and six months after different vaccination regimens and four weeks after an additional booster vaccination. This was a...
by Usha Govindarajulu | Oct 26, 2022 | Biostatistics, Blog, COVID-19, Healtcare, Usha Govindarajulu
October 26, 2022 In a letter to the editor, the authors stated that they previously reported on the incidence of myocarditis in Israel after receipt of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) against coronavirus disease 2019 (Covid-19) to have been the...
by Usha Govindarajulu | Oct 14, 2022 | Biostatistics, Blog, COVID-19, Healtcare
October 13, 2022 A recent article in JAMA, “Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes” focuses on looking at the association of COVID-19 vaccination and boosters or prior infection with...
by Usha Govindarajulu | Sep 30, 2022 | Biostatistics, Blog, COVID-19, Healtcare
September 26, 2022 A recent article in New Medical Life Sciences, “Researchers explore neurological manifestations among long COVID patients” focuses on an article that appeared in Nature Medicine regarding a published study on assessing long-term neurological...
by Usha Govindarajulu | Sep 14, 2022 | Biostatistics, Blog, COVID-19, Healtcare
September 14, 2022 According to a recent article in Nature Communications, regular rapid testing provided two-fold benefits: identifying infectious individuals and providing positive tests sufficiently early during infection that treatment with antivirals can...
by Usha Govindarajulu | Aug 31, 2022 | Biostatistics, Blog, COVID-19, Epidemiology, Healtcare, Usha Govindarajulu
August 31, 2022 In a recent article in NEJM that appeared this month, researchers conducted a double-blind randomized placebo-controlled trial of metformin, ivermectin, and fluvoxamine to study their effectiveness against outcomes related to COVID-19. They used a...
